OHR Pharmaceutical Inc (NASDAQ:OHRP) a clinical-stage pharmaceutical firm advancing novel therapies for ophthalmic ailment, posted financial report for its fiscal year closed September 30, 2017. Dr. Jason Slakter, the CEO, reported that their primary objective at company continues to be the remarkable completion of the MAKO trial, their ongoing clinical study being conducted to assess the safety and efficacy of Squalamine in together with Lucentis® for treatment-naive subjects with the wet form of age-linked macular degeneration.
The MAKO trial registered a targeted population recognized in the prior Phase 2 trial which they consider is best suited for Squalamine combination plan and is consistent with the action mechanism of Squalamine as well as the vascular biology of the ailment. They remain on track to report and receive top-line efficacy report from the MAKO trial in early calendar 2018.
Continued progress of the current clinical trial in wet-AMD, authorized the MAKO trial. The trial is a multi-center, double-masked, randomized, placebo controlled clinical study intended to assess Ohr’s key candidate Squalamine in conjunction with Lucentis in wet-AMD. Topline-data from the trial are projected in 2018.
In April 2017, OHR took a strategic decision to modify the MAKO trial from the original permitted upon design to allow efficacy assessment at an earlier date than initially projected. Over 200 patients were registered in the MAKO trial. Patients obtained monthly Lucentis and either placebo eye drops or topical Squalamine twice daily. The main endpoint is an evaluation of visual acuity gain at 9-months. The MAKO trial prospectively registered the patient population noted from the prior Phase II IMPACT trial that had the greatest prospect to gain from Squalamine combination treatment.
Raised around $19.5 million in total net proceeds, after discounting placement agent fees and providing expenses payable, from 2 public offerings of warrants and common stock that closed on April 10, 2017 and on December 13, 2016.